文献速递药物相互作用

胃酸抑制剂介导的口服药物相互作用系统综述

A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications.
PubMed 文献 · Clin Pharmacokinet · 2020-01-01

该系统综述通过检索多个数据库,全面识别了与胃酸抑制剂(ARAs)发生临床有意义相互作用的121种口服药物,其中38种为胃pH依赖性机制,83种为非胃pH依赖性机制(涉及代谢酶、转运体、螯合、尿液碱化)。另发现109种药物与ARAs无临床有意义相互作用。

要点

  • 121种口服药物与ARAs有临床有意义相互作用,38种为pH依赖,83种为非pH依赖。
  • 非pH依赖机制包括代谢酶、转运体、螯合和尿液碱化。
  • 109种药物未显示与ARAs有临床有意义相互作用。

核心结论

  • 121种口服药物与胃酸抑制剂存在临床有意义相互作用,其中38种为胃pH依赖机制,83种为非胃pH依赖机制。

研究设计与样本

  • 系统综述,检索PDR3D、华盛顿大学药物相互作用数据库、DailyMed、Drugs@FDA.gov和UpToDate/Lexicomp,检索时间为2018年6月1日至8月1日。

主要发现

  • 共121种药物与ARAs有临床有意义相互作用,38种为胃pH依赖,83种为非胃pH依赖(涉及代谢酶、转运体、螯合、尿液碱化)。
  • 另有109种药物经研究未发现与ARAs有临床有意义相互作用。

临床怎么用

  • 临床药师可参考本综述识别与ARAs的临床相关相互作用,避免治疗失败或不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Several review articles have been published discussing gastric acid-related drug-drug interactions (DDIs) mediated by coadministration of antacids, histamine H2 receptor antagonists, or proton pump inhibitors, but are not sufficiently comprehensive in capturing all documented DDIs with acid-reducing agents (ARAs) and tend to focus on gastric pH-dependent DDIs and/or basic drugs. Subsequently, several new drugs have been approved, and new information is available in the literature. The objective of this systematic review is to comprehensively identify oral medications that have clinically meaningful DDIs, including loss of efficacy or adverse effects, with gastric ARAs, and categorize these medications according to mechanism of interaction. METHODS: An indepth search of clinical data in the PDR3D: Reed Tech Navigator™ for Drug Labels, University of Washington Drug-Drug Interaction Database, DailyMed, Drugs@FDA.gov, and UpToDate®/Lexicomp® Drug and Drug Interaction screening tool was conducted from 1 June to 1 August 2018. The PDR3D, University of Washington Drug-Drug Interaction Database, and DailyMed were searched with terms associated with gastric acid and ARAs. Conflicting findings were further investigated using the UpToDate®/Lexicomp® screening tool. Clinical relevance was assessed on whether an intervention was needed, and prescribing information and/or literature supporting the DDI. RESULTS: Through the search strategy, 121 medications were found to clinically meaningfully interact with ARAs. For 38 medications the mechanism of interaction with ARAs was identified as gastric pH dependent, and for 83 medications the interaction was found to be not gastric pH mediated, with mechanisms involving metabolic enzymes, transporters, chelation, and urine alkalization. Additionally, 109 medications were studied and did not have a clinically meaningful interaction with ARAs. CONCLUSION: This review may provide a resource to healthcare professionals in aiding the care of patients by increasing awareness of interactions with ARAs and may also identify and potentially aid in avoiding clinically relevant DDIs and preventing risk of treatment failure and/or adverse effects. Advances in non-clinical predictions of gastric pH-mediated DDIs may guide the need for a future clinical evaluation.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Patel D, Bertz R, Ren S, et al. A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications. Clin Pharmacokinet. 2020. PMID: 31788764. doi:10.1007/s40262-019-00844-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。